Evidence map›Paper›PMID 41646305›Full record

ArticleResearch square2026

Acute amyloid-β exposure disrupts insulin signaling in blood-brain barrier endothelial cell culture models.

Douglas A Nelson, Suresh K Swaminathan, Hannah S Seo, Samira M Azarin, Krishna R Kalari, Karunya K Kandimalla

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Douglas A NelsonUniversity of Minnesota.
Suresh K SwaminathanUniversity of Minnesota.
Hannah S SeoUniversity of Minnesota.
Samira M AzarinUniversity of Minnesota.
Krishna R KalariMayo Clinic.
Karunya K KandimallaUniversity of Minnesota.

Funding

Amyloid beta peptides and type-2 diabetes sequelae synergistically inhibit insulin signaling and trafficking at the blood brain barrierR01NS125437 · NINDS · UNIVERSITY OF MINNESOTA · PI KARUNYA KUMAR KANDIMALLA, VAL JOHN LOWE · 2022 to 2026
$2.6M
CRCNS: Deep Learning to Discover Neurovascular Disruptions in Alzheimer's DiseaseR01AG085900 · NIA · UNIVERSITY OF MINNESOTA · PI Carlos Fernandez-Granda, Mikel Hernaez · 2023 to 2026
$1.2M
NIA NIH HHS R01 AG085900NINDS NIH HHS R01 NS125437
6 · The paper itself

Abstract

Background: Brain insulin resistance and cerebrovascular dysfunction emerge early in late-onset Alzheimer's disease, but how amyloid-β (Aβ) disrupts insulin signaling at the cerebrovascular blood-brain barrier-a major site of insulin receptor signaling and transport into the brain-remains unclear. Methods: We exposed two distinct human blood-brain-barrier endothelial cell models to soluble Aβ40 or Aβ42 for 1 h, followed by 100 nM insulin for 10 min. Protein and phosphoprotein responses were quantified by reverse-phase protein array, and differential expression was evaluated using linear models. Results: Aβ40 reduced insulin-stimulated Akt activation and converted insulin's normal inhibition of AMPK into modest stimulation. Aβ42 did not alter insulin-stimulated Akt signaling but moderately suppressed basal Akt activation. Conclusions: These findings suggest that Aβ40 acutely impairs insulin signal transduction in BBB endothelial cells, supporting a model in which vascular Aβ exposure contributes directly to the early development of brain insulin resistance in AD.

Indexed as

Akt signalingAlzheimer’s diseaseamyloid-βblood–brain barrierendothelial cellsinsulin signalingreverse-phase protein array

Identifiers

PMID41646305
PMCPMC12869616

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.